F8 and hemophilia A: To examine the therapeutic potential of hBS910, its FVIII-mimetic activity was compared with human FVIII by using thrombin generation assay (TGA) [23], [35], [36] in commercially available human FVIII-deficient plasma which was derived from a single donor with severe hemophilia A without FVIII inhibitors (Fig. 7A).